
Latest Science News
AI and Physics-Based Modeling Identifies New Parkinson’s Drug
Gain Therapeutics' GT-02287, an allosteric modulator of glucocerebrosidase (GCase), restores enzyme function in preclinical Parkinson's models, reducing neuroinflammation and neurodegeneration. The Magellan platform uses AI and structural modeling to target allosteric sites. Phase 1b results expected Q4 2025, with Phase 2 in 2026.
New Discovery Offers Hope for Friedreich's Ataxia
Researchers found lowering FDX2 levels compensates for frataxin loss by restoring iron-sulfur cluster production in cells. Using worm models under hypoxia, mutations in FDX2 and NFS1 enabled survival in normal oxygen. Verified in mouse and human cells, suggesting druggable targets.
Brain Switch ΔFosB Could Rewrite Mental Illness Treatment
ΔFosB accumulates in reward circuits during stress or drug exposure, causing long-term gene expression changes linked to addiction and mood disorders. Findings from animal and human brain studies highlight its role in vulnerability. Supports resilience-focused therapies.